For decades, the fight against atherosclerosis has focused mainly on preventing plaque from getting worse. Lowering LDL cholesterol, controlling blood pressure, avoiding tobacco and treating other cardiovascular risk factors can substantially reduce the chance of heart attack and stroke.
But researchers have also been asking a more ambitious question: Can we actively remove some of the cholesterol already trapped inside an artery wall?
That question is behind research into a protein sometimes described as a “sponge” for cholesterol.
The science is fascinating, but the headlines need a little context. This isn’t a treatment that can currently be used to simply “clean out” blocked arteries. It is an experimental approach being investigated in people with cardiovascular disease.
What Is Actually Blocking the Arteries?
Atherosclerosis develops gradually. LDL cholesterol and other materials can accumulate within artery walls, alongside immune cells, connective tissue and other cellular debris.
Over time, some plaques become large enough to narrow an artery. More importantly, certain plaques can become unstable and rupture, potentially triggering a blood clot that blocks blood flow and causes a heart attack or stroke.
That means cardiovascular disease isn’t simply a plumbing problem where a pipe becomes clogged. Plaque is living, biologically active tissue, influenced by cholesterol, inflammation and the immune system.
This is one reason researchers are interested in therapies that could potentially change the composition of an existing plaque rather than simply slowing the formation of new deposits.
Meet ApoA-I: The “Sponge” Behind the Idea
The protein at the center of this research is apolipoprotein A-I, or ApoA-I.
ApoA-I is the main protein component of HDL particles. One of its important biological roles is helping transport cholesterol away from tissues and toward the liver, where it can ultimately be processed and eliminated.
Researchers have explored whether giving patients an infusion containing ApoA-I could temporarily increase the body’s ability to remove cholesterol from atherosclerotic plaques.
MultiMedica in Italy has been involved in the clinical research surrounding this approach. Its researchers describe ApoA-I as acting somewhat like a sponge because it can bind cholesterol and help move it away from plaque.
The idea is remarkably different from simply lowering cholesterol in the bloodstream.
Instead of asking only, “How do we stop more cholesterol from entering the plaque?”, scientists are asking, “Can we encourage some of the cholesterol already inside the plaque to leave?”
From Laboratory Idea to Human Research
The concept isn’t entirely new.
Researchers have studied unusual forms of ApoA-I for decades, including the famous ApoA-I Milano variant identified in people from the Italian town of Limone sul Garda. Subsequent research helped fuel interest in whether ApoA-I could be harnessed therapeutically.
More recently, scientists developed CSL112, an investigational formulation of ApoA-I designed for intravenous administration.
The AEGIS-II trial was designed as a large phase 3 study involving patients who had recently experienced an acute myocardial infarction. MultiMedica was among the Italian centers involved.
That distinction matters.
A therapy being tested in people after a heart attack is very different from a future treatment that could routinely remove established plaque in otherwise healthy people.
Why the “Clean Arteries” Headline Needs a Reality Check
It is tempting to imagine an artery being scrubbed clean from the inside.
Biology isn’t that simple.
Atherosclerotic plaques contain cholesterol, calcium, inflammatory cells, fibrous tissue and other materials. Even if a therapy successfully removes some cholesterol from a plaque, that doesn’t necessarily mean the entire blockage disappears.
Researchers are also interested in plaque stability. A smaller or more stable plaque could potentially be less dangerous, but demonstrating that a biological change actually prevents heart attacks and strokes requires large, carefully controlled clinical trials.
MultiMedica’s own description of the AEGIS-II research emphasizes that the important question is whether the treatment can reduce recurrent cardiovascular events after an acute coronary syndrome—not simply whether it can make an artery look cleaner on an image.
How Is This Different From Statins?
Statins remain one of the most important tools for reducing cardiovascular risk.
They work primarily by lowering LDL cholesterol, which reduces the amount of cholesterol available to contribute to atherosclerotic disease. Other modern cholesterol-lowering medicines can also produce substantial reductions in LDL.
ApoA-I-based therapy is conceptually different because it aims to promote cholesterol removal from existing plaque.
That doesn’t mean one approach replaces the other.
In future cardiovascular medicine, different treatments could potentially have complementary roles: lowering circulating LDL while encouraging cholesterol already trapped within plaque to move out.
But that possibility has to be demonstrated through clinical evidence rather than assumed from a promising biological mechanism.
Why This Research Matters
Cardiovascular disease remains one of the world’s major health problems. Atherosclerosis can develop silently for years before producing symptoms.
That makes prevention especially important.
At the same time, researchers are increasingly interested in treatments that don’t merely slow disease progression but could potentially modify existing disease.
The ApoA-I approach represents that shift in thinking.
Instead of treating plaque as a permanent structure that can only be bypassed or stabilized, scientists are investigating whether the body’s own cholesterol-transport system can be enhanced to encourage some plaque cholesterol to leave.
That is an exciting scientific question—even if the ultimate clinical benefit remains the most important test.
What Can You Do While Researchers Keep Testing It?
There is no reason to wait for an experimental therapy to take cardiovascular health seriously.
The strongest evidence today still supports controlling the factors known to drive atherosclerosis.
That includes maintaining healthy cholesterol levels, managing blood pressure, avoiding tobacco, staying physically active and eating a balanced diet rich in vegetables, fruits, whole grains, legumes, nuts and other minimally processed foods.
For people who already have cardiovascular disease or high cholesterol, prescribed treatment should not be stopped or replaced with an experimental approach without medical advice.
The Future May Be About Reversing Disease
The most interesting part of the ApoA-I research isn’t the catchy “sponge” nickname.
It’s the possibility that cardiovascular medicine could eventually move beyond simply preventing plaque from growing toward actively changing the biology of plaque that is already there.
Researchers are still working out whether that strategy can translate into fewer heart attacks and other cardiovascular events.
So, for now, there is no magic protein that can simply wash blocked arteries clean.
But the underlying idea is real, the research is substantial, and the question it raises is genuinely exciting: Could medicine one day help the body remove some of the cholesterol it has already stored inside an artery?
That answer is still being worked out in clinical trials—and that is exactly where promising science belongs before it becomes standard care.
Photo by Turgay Koca: https://www.pexels.com/photo/abstract-yellow-painting-15275676/